LL-37 side effects and safety context

The most useful safety fact about LL-37 is not a symptom list — it is a ratio. Structural and functional work published in the Journal of Biological Chemistry (PMID 9452503) found LL-37 antibacterially effective against E. coli at roughly 5 µM and cytotoxic to eukaryotic cells at 13–25 µM. Two- to fivefold separates the concentration that kills bacteria from the concentration that damages your own cells. That is a narrow therapeutic window by any standard, and it is a property of the molecule rather than of a particular product.

Several published characteristics compound that narrowness:

• Non-selectivity. Membrane work in Biochemical Journal (PMID 10417311) characterized LL-37's action on negatively charged membranes as a detergent-like "carpet" effect, framed explicitly around the molecular basis for its non-cell-selective activity. It does not distinguish microbial from mammalian membranes as cleanly as the marketing implies.
• Environmental dependence. The same JBC study found LL-37 disordered in water, helical in the presence of certain anions, with helicity tracking potency — and helical content falling at pH below 5. Its activity is a function of where it lands, not just how much was delivered.
• Serum inhibition. Human serum inhibited both the antibacterial and the cytotoxic activities. Effects observed in a buffer do not straightforwardly predict effects in blood, in either direction.

A compound whose behaviour flips with concentration, pH, and ionic environment is one where "I took a small amount" is not a safety argument, because the local concentration at the tissue is what matters and it is not something a user can know.

Two landmark papers describe LL-37 driving human disease rather than resolving it, and both used administration experiments rather than mere correlation.

In rosacea, a Nature Medicine study (PMID 17676051) found patients express abnormally elevated cathelicidin in facial skin, in differently processed forms than healthy controls. Injecting the rosacea-associated cathelicidin peptides into mouse skin caused inflammation; deleting the cathelicidin gene blocked it. In psoriasis, a Nature paper (PMID 17873860) showed LL-37 binds self-DNA and carries it into endosomal compartments of plasmacytoid dendritic cells, triggering type I interferon and breaking the normal tolerance to one's own DNA — an autoimmune-initiating step attributed to the peptide itself.

These are mechanistic demonstrations of harm, published in the same literature cited to support LL-37's benefits.

Tolerability data exist, but only for one route. In the 2014 first-in-man study, 34 patients received twice-weekly topical LL-37 on venous leg ulcers at 0.5, 1.6, or 3.2 mg/mL for four weeks, and the authors reported no safety concerns regarding local or systemic adverse events (PMID 25041740). The 148-patient phase IIb reported the study drug well tolerated and safe at both 0.5 and 1.6 mg/mL (PMID 34687253).

Read carefully, that record has a shape. The concentrations were low. The application was onto a wound surface, not into circulation. And in the 2014 trial the highest concentration lost the efficacy the lower ones showed — consistent with the cytotoxic ceiling, and a reminder that the dose-response here is not a line that keeps rising. No trial has evaluated systemic or injected LL-37 for safety in people.

LL-37 is marketed with the implication that a molecule your neutrophils already make must be gentle to add. The rosacea and psoriasis literature is the direct refutation: dysregulated cathelicidin is a disease mechanism, and the body controls it through tightly regulated expression, processing, and location — none of which a vial reproduces. Add to that the absence of any approved product, meaning no verified concentration, sterility, or purity, and the honest position is that the risk profile of administered LL-37 outside a low-concentration topical wound setting is simply not characterized.